Related by context. All words. (Click for frequent words.) 79 breast cancers 78 cancers 77 colorectal cancers 76 ovarian cancers 75 lung cancers 74 pancreatic cancers 74 tumors 74 bladder cancers 73 breast tumors 73 prostate cancer 73 prostate tumors 73 colorectal cancer 71 endometrial cancers 71 lung tumors 70 colon cancers 70 malignancy 70 melanoma 70 melanomas 69 malignancies 69 ovarian cancer 69 colorectal tumors 68 bowel cancers 68 metastatic prostate cancer 67 squamous cell carcinomas 67 adenocarcinoma 67 ovarian tumors 67 gastric cancers 66 lobular carcinoma 66 DCIS 66 neuroendocrine tumors 66 colorectal cancer CRC 65 lymphomas 65 carcinoma 65 malignant tumors 65 colon cancer 65 PCa 65 prostate tumor 65 pre cancerous lesions 65 bladder cancer 64 metastases 64 gastric cancer 64 adenocarcinomas 64 testicular cancers 64 cervical lesions 64 endometrial cancer 64 oropharyngeal cancer 64 metastatic disease 64 nonmelanoma skin cancers 64 skin cancers 64 basal cell carcinomas 64 adenomas 64 anaplastic 64 breast cancer 64 CaP 64 metastatic cancer 64 invasive breast cancer 63 rectal cancers 63 lung cancer 63 pancreatic tumors 63 HNSCC 63 seminoma 63 pre cancerous growths 63 NSCLC 63 gliomas 63 adenoma 63 BRCA mutations 63 gastrointestinal cancers 63 precancerous lesions 63 prostate cancer CaP 63 invasive cervical cancer 63 cancer 63 grade gliomas 63 glioblastomas 63 GISTs 62 squamous cell 62 malignant melanoma 62 pre cancerous polyps 62 cervical cancers 62 melanoma tumors 62 carcinomas 62 squamous cell cancers 62 thyroid cancers 62 neoplasia 62 curable cancers 62 uterine cancers 62 premalignant 62 colorectal polyps 62 HER2 positive 62 brain tumors 62 micrometastases 62 pancreatic adenocarcinoma 62 squamous cell skin 62 metastasis 62 premalignant lesions 61 rectal cancer 61 advanced adenomas 61 benign growths 61 ductal breast cancer 61 breast ovarian 61 gynecologic cancers 61 precancers 61 serous ovarian cancer 61 hepatocellular carcinoma 61 HER2 positive breast cancer 61 osteosarcomas 61 distant metastases 61 squamous cell carcinoma 61 ductal cancer 61 differentiated thyroid 60 esophageal cancers 60 BRCA1 mutations 60 lobular cancer 60 invasive carcinoma 60 neoplasms 60 atypical hyperplasia 60 malignant growths 60 colon tumors 60 colon polyps 60 carcinoid cancer 60 HPV infections 60 precursor lesions 60 breast endometrial 60 renal cell carcinomas 60 prostate specific 60 basal cell carcinoma 60 tumor 60 prostate pancreatic 60 metastatic tumors 60 squamous cell cancer 60 thyroid nodules 60 nonsmall cell lung cancer 60 glioblastoma 60 testicular germ cell 60 Barrett esophagus 60 carcinoid tumors 60 ductal carcinoma 59 liver metastases 59 ovarian lung 59 neuroblastomas 59 pancreatic lung 59 situ DCIS 59 adenomatous polyps 59 lymph node metastases 59 fibroadenomas 59 benign polyps 59 soft tissue sarcomas 59 cancerous cells 59 prostate cancer CRPC 59 seminomas 59 colorectal polyp 59 malignant melanomas 59 cell carcinoma 59 metastatic 59 carcinoid 59 pancreatic cancer 59 EGFR mutation 59 malignant lesions 59 breast lesions 59 metastatic lesions 59 estrogen receptor negative 59 renal cell carcinoma 59 lobular breast cancer 59 liver cancer 59 cervical cancer 59 Prostate cancer 59 prostate adenocarcinoma 59 abnormal growths 59 HPV infection 59 sarcosine 59 advanced adenoma 59 HER2 positive cancers 59 localized prostate cancer 59 cancerous lesions 59 bladder tumors 59 metastatic colorectal 59 breast carcinomas 59 mesotheliomas 59 precancerous tumors 59 GBM tumors 59 prostate specific antigen 59 lung adenocarcinoma 59 cisplatin resistant 58 pre cancerous cells 58 neoplasias 58 Ovarian cancer 58 esophageal adenocarcinoma 58 prostate cancer PCa 58 oesophageal cancer 58 breast cancer recurrence 58 anal cancers 58 distant metastasis 58 uveal melanoma 58 HPV 58 colorectal gastric 58 prostrate cancer 58 ccRCC 58 sarcomas 58 cell lung cancer 58 cancerous tumors 58 medullary thyroid cancer 58 lung nodules 58 precancerous 58 precancerous cervical lesions 58 tumor cells 58 cancerdefine 58 invasive ductal 58 prostate tissue 58 epithelial tumors 58 basal cell 58 antigen PSA 58 sentinel nodes 58 tumor recurrence 58 gynecological cancers 58 colorectal breast 58 axillary lymph nodes 58 cutaneous melanoma 58 Cancers 58 polyps 58 GIST tumors 58 urothelial carcinoma 58 benign tumors 58 Stomach cancer 58 bone metastasis 58 metastatic cancers 58 metastatic colon cancer 58 basal cell carcinoma BCC 57 leukaemias 57 poorer prognosis 57 pleural mesothelioma 57 metastatic melanomas 57 bowel cancer 57 lymphoma 57 hormone receptor positive 57 basal cell cancers 57 HER2 positive tumors 57 breast carcinoma 57 precancerous growths 57 situ LCIS 57 BRCA2 mutations 57 cervical carcinoma 57 mammary tumors 57 colorectal 57 prostate 57 Basal cell 57 precancerous polyps 57 Colon polyps 57 periodontitis 57 mammary cancers 57 lung colorectal 57 MYCN amplification 57 Colorectal cancer 57 benign breast 57 Glioblastoma 57 Testicular cancer 57 Tumors 57 hereditary breast cancer 57 MGUS 57 pre malignant lesions 57 hepatocellular carcinoma HCC 57 Tumours 57 HGPIN 57 molecular abnormalities 57 skeletal metastases 57 invasive ductal carcinoma 57 malignant pleural mesothelioma 57 papillary 57 prostate lung 57 NAFLD 57 neuroendocrine cancers 57 metastatic breast cancer 57 colon breast 57 endometrial tumors 57 ALCL 57 prostate breast 57 EGFR mutations 57 squamous cell carcinoma SCC 57 epithelial ovarian cancer 57 Hepatocellular Carcinoma HCC 57 hormone deprivation 57 gynecologic cancer 56 neuroendocrine carcinoma 56 renal tumors 56 cancerous growths 56 Squamous cell carcinomas 56 castration resistant prostate cancer 56 familial pancreatic cancer 56 malignant prostate 56 endometrial hyperplasia 56 prostate carcinoma 56 precancer 56 nasopharyngeal carcinoma 56 chlamydial infection 56 hormonal therapies 56 renal carcinoma 56 Cholangiocarcinoma 56 nodular melanoma 56 esophageal cancer 56 ADPKD 56 lung pancreatic 56 intestinal polyps 56 axillary dissection 56 B7 H3 56 peritoneal cancer 56 Bladder cancer 56 ovarian breast 56 PSA velocity 56 BRAF gene 56 colorectal lung 56 brain metastases 56 PSA screening 56 colorectal carcinoma 56 grade cervical intraepithelial 56 pituitary adenomas 56 PCNSL 56 ovarian 56 TGFBR1 * 6A 56 elevated CRP 56 Gastric cancer 56 malignant transformation 56 incidentalomas 56 GnRH agonists 56 solid tumors 56 meningiomas 56 pre cancerous 56 gastric adenocarcinoma 56 abnormal mammograms 56 testicular cancer 56 cancerous polyps 56 noncancerous tumors 56 gastrointestinal stromal tumors 56 BRCA2 56 EUS FNA 56 MSMB 56 specific antigen 56 penile cancers 56 Basal cell carcinoma 56 liver metastasis 56 medulloblastomas 56 Acoustic neuromas 56 BRCA mutation 56 basal cell cancer 56 metastatic melanoma 56 hepatocellular cancer 56 atherosclerotic lesions 56 pCR 56 nonmelanoma skin cancer 56 HER2 overexpression 55 colorectal neoplasms 55 BRAF mutation 55 malignant lymphoma 55 p# mutations 55 metastatic lung cancer 55 CIN3 55 benign lesions 55 BRCA deficient 55 follicular lymphoma 55 urothelial cancer 55 Polyps 55 postmenopausal breast cancer 55 lymph node involvement 55 Colorectal cancers 55 chronic prostatitis 55 Squamous cell 55 HER2 negative 55 HPV# 55 Cristofanilli 55 epithelial cancers 55 non Hodgkin lymphoma 55 Squamous cell carcinoma 55 esophageal squamous cell carcinoma 55 hamartomas 55 malignant neoplasm 55 oophorectomy 55 contralateral breast 55 Melanomas 55 chromosomal abnormalities 55 cell carcinomas 55 ovarian carcinoma 55 sentinel lymph node biopsy 55 neoplasm 55 systemic scleroderma 55 Adjuvant chemotherapy 55 Glioblastoma multiforme GBM 55 Carcinoma 55 Papillary 55 breast prostate 55 metastatic colorectal cancer 55 KRAS mutation 55 laryngeal cancer 55 pancreatic NET 55 adenomatous polyp 55 metastatic prostate 55 peritoneal carcinomatosis 55 gallstone disease 55 basal cell nevus syndrome 55 pulmonary metastases 55 PSADT 55 breast colon 55 ovarian pancreatic 55 Malignant tumors 55 cervical dysplasia 55 hormonal therapy 55 BRCA mutation carriers 55 glioma 55 uterine ovarian 55 HCV infection 55 DCIS lesions 55 cervical intraepithelial neoplasia 55 noncancerous cells 55 recurrent prostate cancer 55 alveolar rhabdomyosarcoma 55 tumor subtypes 55 prostate biopsies 55 squamous cell lung cancer 55 estrogen receptor positive 55 HER2 55 malignant cells 55 Metastatic 55 cervical breast 55 osteosarcoma 55 BRCA1 55 metachronous 55 lobular carcinomas 55 genital herpes infections 55 pituitary tumors 55 endocrine tumors 55 uterine cancer 55 castrate resistant 55 prostate ovarian 55 EGFR 54 malignant gliomas 54 adjuvant radiation 54 synovial sarcoma 54 dutasteride 54 Carcinoid tumors 54 PKCi 54 occult metastases 54 cranial radiation 54 mucinous 54 Rectal cancer 54 nonseminoma 54 oral squamous cell 54 locoregional recurrence 54 intestinal metaplasia 54 preoperative chemotherapy 54 commonly mutated genes 54 CLL 54 pancreatic tumor 54 operable breast cancer 54 colonic polyps 54 pre cancerous lesion 54 neoplastic lesions 54 leukaemic stem cells 54 testicular tumors 54 esophageal tumors 54 oligodendrogliomas 54 BRCA1 mutation 54 invasive lobular 54 Gliomas 54 glioblastoma multiforme 54 Squamous 54 superficial bladder cancer 54 oesophageal adenocarcinoma 54 gynecologic malignancy 54 neoadjuvant therapy 54 denser breasts 54 breast uterine 54 hormone refractory 54 mutated KRAS gene 54 serum PSA 54 breast cancer subtypes 54 BRAF mutations 54 malignant neoplasms 54 medulloblastoma 54 Sjögren syndrome 54 EBV infection 54 pancreatic carcinoma 54 genes BRCA1 54 atypia 54 leiomyomas 54 grade serous ovarian 54 CIN3 + 54 gynecological cancer 54 metastatic basal cell 54 Pancreatic cancer 54 premenopausal breast cancer 54 Lung cancer 54 metastatic gastric 54 human papillomavirus HPV 54 Malignant melanoma 54 vulvar intraepithelial neoplasia 54 malignant polyps 54 breast pancreatic 54 liver fibrosis 54 breast cancer metastasis 54 lung carcinomas 54 ductal 54 precancerous spots 54 astrocytoma 54 acute myelogenous leukemia AML 54 glandular tissue 54 ductal carcinomas 54 CYT# potent vascular disrupting 54 androgens 54 grade dysplasia 54 HCV infections 54 Metastases 54 MALT lymphoma 54 squamous 54 radiation therapy SBRT 54 transitional cell carcinoma 54 atypical ductal hyperplasia 54 gastric carcinoma 54 BRCA1 gene 54 colorectal adenomas 54 ASCUS 54 estrogen receptors 54 leukemias 54 HPV types 54 angiosarcoma 54 metastatic bladder 53 BRCA2 gene mutation 53 prostate cancer AIPC 53 Brain metastases 53 CIN2 + 53 isoflavones 53 precancerous colon polyps 53 neoadjuvant chemotherapy 53 progesterone receptor negative 53 papillary carcinoma 53 subclinical hyperthyroidism 53 node metastases 53 Stat5 53 lung adenocarcinomas 53 Her2 53 ependymoma 53 KRAS oncogene 53 GNAQ 53 sarcomatoid 53 colorectal adenoma 53 medically inoperable 53 benign proliferative breast 53 isothiocyanates 53 PARP inhibitors 53 Uterine fibroids 53 biopsies 53 malignant nodules 53 sarcoma 53 HbF 53 aneuploid cells 53 precancerous cervical 53 Esophageal cancer 53 prostate colon 53 ALK mutations 53 adjuvant therapy 53 gastrointestinal GI cancers 53 cervical neoplasia 53 adenoid cystic carcinoma 53 sentinel node biopsy 53 hedgehog pathway 53 estrogen receptor ER 53 BRCA carriers 53 Ductal carcinoma 53 pilocytic astrocytomas 53 FGFR2 53 Cell Lung Cancer 53 specific antigen PSA 53 recurrent ovarian cancer 53 breast cancer gene mutation 53 polyp recurrence 53 endometrial carcinoma 53 surgical biopsies 53 grade glioma 53 undergoing radical prostatectomy 53 frequently benign tumor 53 colorectal neoplasia 53 postoperative pathology 53 precancerous cells 53 untreated celiac disease 53 resectable 53 Pancreatic neuroendocrine tumors 53 endometrial ovarian 53 advanced neoplasia 53 IGF 1R 53 carcinoid tumor 53 H. pylori eradication 53 WT1 53 adenomatous 53 lymph node removal 53 HER2 + 53 neuroblastoma tumors 53 androgen deprivation 53 Non Hodgkin lymphoma 53 Radical prostatectomy 53 squamous cells 53 non Hodgkin lymphomas 53 recurrent ovarian 53 EZH2 53 potentially cancerous growths 53 pancreatic 53 Hurthle cell 53 sentinel node 53 glioblastoma tumors 53 uterine tumors 53 oropharyngeal cancers 53 Glioblastoma multiforme 53 mitochondrial fusion 53 cancerous 53 Malignant Melanoma 53 autoantibodies 53 invasive lobular carcinoma 53 armpit lymph nodes 53 cell lymphomas 53 Follicular lymphoma 53 BRCA2 mutation 53 atherosclerotic disease 53 indolent lymphoma 53 mutated BRCA1 53 melanoma skin 53 prostate carcinomas 53 polycystic ovarian syndrome PCOS 53 cystectomy 53 IDH1 mutation 53 colorectal liver metastases 53 anthracyclines 53 invasive ductal carcinomas 53 invasive cervical cancers 53 leiomyosarcoma 53 MSH2 53 paragangliomas 53 nodal metastasis 53 androgen therapy 53 adjuvant radiotherapy 53 anal lesions 53 chromosomal rearrangement 53 SETDB1 53 metastatic renal cell carcinoma 53 BRCA1 mutation carriers 53 gum disease 53 micronuclei 53 disease 53 Glioblastoma Multiforme GBM 53 H. pylori infection 52 precancerous polyp 52 Melanoma 52 lymphatic tissue 52 cytoreductive surgery 52 aromatase 52 malignant 52 screening mammography 52 cancerous breast 52 BRCA2 gene mutations 52 bowel polyps 52 carcinoma HNSCC 52 Androgen deprivation therapy 52 olaparib 52 childhood leukemias 52 spontaneously regress 52 Burkitt lymphoma 52 androgen deprivation therapy 52 DLBCL 52 micrometastasis 52 hyperplastic polyps 52 cardiovascular disease 52 epithelial ovarian 52 faulty BRCA2 gene 52 Renal cell carcinoma 52 prophylactic mastectomy 52 faulty BRCA genes 52 solar keratosis 52 glioma rarer 52 HER2 amplification 52 adrenocortical cancer 52 ductal adenocarcinoma 52 pancreatic prostate 52 nonmelanoma 52 nonalcoholic steatohepatitis NASH 52 CLL cells 52 lung metastasis 52 ependymomas 52 bile duct cancers 52 castrate resistant prostate cancer 52 hormone receptor negative 52 melanoma lesions 52 GBV C 52 mesothelin 52 choriocarcinoma 52 urinary symptoms 52 LRP5 52 Adenocarcinoma 52 Oesophageal cancer 52 mammary cells 52 malignant brain 52 APOL1 52 pancreatic cysts 52 prostate bladder 52 imatinib Gleevec 52 prognostic indicator 52 sporadic ALS 52 cyclin E 52 narcolepsy cataplexy 52 cancerous enlargement 52 proliferative diabetic retinopathy 52 Epstein Barr virus EBV 52 inherited mutations 52 EGFR blockers 52 neoplastic 52 lung metastases 52 HER2 receptor 52 AAT deficiency 52 luminal cells 52 androgen receptors 52 proximal colon 52 c MYC 52 disease progression 52 distal colon cancer 52 BRCA genes 52 CMV infection 52 metastatic lymph nodes 52 urinary tract symptoms LUTS 52 oligodendroglioma 52 Li Fraumeni 52 mutated genes 52 gastrointestinal stromal tumor 52 familial ALS 52 diffuse gastric 52 DHFR 52 Basal cell carcinomas 52 malignant pancreatic 52 Barrett Esophagus 52 overexpress HER2 52 NMP# 52 unnecessary biopsies 52 PCA3 scores 52 hormonally sensitive 52 varicocele 52 fibrocystic disease 52 metastatic RCC 52 pancreatic ovarian 52 PTEN gene 52 HER2 expression 52 Thyroid cancer 52 clinically localized prostate 52 estrogen receptor 52 Thyroid nodules 52 KRAS mutations 52 liposarcoma 52 amyloid deposits 52 ocular melanoma 52 Prostatitis 52 Kaposi sarcoma 52 myelofibrosis polycythemia vera 52 Helicobacter pylori infection 52 oropharyngeal squamous cell carcinoma 52 androgen suppression therapy 52 TMEM#B 52 urothelial bladder cancer 52 axillary lymph node dissection 52 EGFR protein 52 pelvic malignancies 52 prognostic markers 52 myelodysplastic syndrome MDS 52 FGFR1 52 SPINK1 52 ApoE4 52 liver scarring 52 cholangiocarcinoma 52 metastatic malignant melanoma 52 Digital Mammographic Imaging 52 Metastatic melanoma 52 gene BRCA2 52 colon polyp 52 fibrocystic changes 52 HER2 positive breast 52 cystatin C 52 cisplatin 52 genetic alterations 52 oesophageal 52 basal cells 52 EBRT 52 abnormal cervical 52 lymph nodes 51 benign enlargement 51 gamma tocopherol 51 prostate walnut 51 disease NAFLD 51 PARP inhibition 51 hormone therapy estrogen 51 basal cell skin 51 mutations 51 genomic alterations 51 abnormal Pap 51 EGFR inhibitors 51 K ras gene 51 gynecological malignancies 51 tumor progression 51 nasopharyngeal cancer 51 chronic lymphocytic leukemia CLL 51 prostate cancer metastases 51 mitochondrial mutations 51 DCIS ductal carcinoma 51 Recurrences 51 ERCC1 51 thyroid cancer 51 pharyngeal cancer 51 gene rearrangements 51 IDH mutations 51 castration resistant 51 gene fusions 51 axillary node dissection 51 abiraterone 51 activating mutations 51 prostate abnormalities 51 venous blood clots 51 CMV disease 51 dysglycemia 51 K ras mutations 51 Uterine cancer 51 neurofibromas 51 adjuvant therapies 51 FLT3 51 varicoceles 51 leukemia ALL 51 PIK3CA 51 lymph node metastasis 51 lung cancer NSCLC 51 sCJD 51 meningioma 51 BMPR2 51 situ CIS 51 mtDNA mutations 51 pediatric malignancies 51 intraductal 51 non squamous NSCLC 51 ovarian hormones 51 Wilms tumor 51 K ras 51 factor receptor 51 myelomas 51 Alessandro Riva 51 malignant cancerous 51 androgen independent 51 tumoral 51 breast cancer genes BRCA1 51 indolent tumors 51 Glioma 51 biochemical recurrence 51 alpha carotene 51 GSTT1 51 completely resected 51 mammographically 51 PTEN protein 51 NSCLC tumors 51 p# mutation 51 neuroblastoma 51 bone metastases 51 tamoxifen 51 clinically detectable 51 antiestrogen 51 gene variants 51 prolongs survival 51 colon rectal cancer 51 colorectal cancer screening 51 pancreatic colon 51 hereditary predisposition 51 elevated triglyceride levels 51 histological subtype 51 ruptured aneurysms 51 bilateral oophorectomy 51 breast biopsies 51 ovarian cervical 51 retinoblastoma 51 Prostate Cancer Prevention 51 serrated polyps 51 benign noncancerous 51 Seewaldt 51 lipid abnormalities 51 familial adenomatous polyposis 51 GSTP1 51 Meningiomas 51 cutaneous squamous cell carcinoma 51 carcinogenesis 51 Colorectal cancer screening 51 nonmetastatic 51 Adenomas 51 genital tract infections 51 colorectal bladder 51 oncogenic HPV types 51 oncoprotein 51 HNPCC 51 endometrial kidney 51 transthyretin 51 NF1 51 lymph node biopsies 51 breast tissue 51 colon pancreas 51 detecting colorectal cancer 51 androgen receptor 51 Inflammatory breast cancer 51 colon pancreatic 51 urate 51 breast lumps 51 TCF#L# 51 relapsed ovarian cancer 51 nonhormonal 51 detect precancerous lesions 51 lipomas 51 metastatic HER2 positive 51 metastatic kidney 51 polyp detection 51 CT colonography 51 hepatoma 51 hypermethylation 51 hormone therapy 51 tumor metastases 51 HPVs 51 acute leukemias 51 glioblastoma tumor 51 CIN2 51 leukemias lymphomas 51 intravenous bisphosphonates 51 locoregional 51 oncogenes 51 surgical biopsy 51 premalignant lesion 51 Prostate Cancer 51 hyperplastic 51 senescent cells 51 molecular subtypes 51 slow metabolizers 51 lung prostate 51 clusterin 51 antitumor effect 51 benign nodules 51 B Cell Lymphoma 51 testosterone supplementation 51 invasive bladder 51 cystic lesions 51 anaplastic lymphoma kinase ALK 51 HG PIN 51 germline mutations 51 carotid stenosis 51 Enlarged prostate 51 BRCA2 carriers 51 ductal lobular 51 breast cancer recurrences 51 colorectal pancreatic 51 #.#ng/ml 51 Prostate Specific Antigen PSA 51 ErbB2 positive 51 cardiotoxicity 51 EGFRvIII 51 urate levels 51 polyps growths 51 abnormal Pap smears 51 Glioblastomas 51 genistein 51 BRCA gene mutations 51 aneuploidy 51 EGF receptor 51 PGDH 51 NF kB pathway 51 fallopian tube carcinoma 51 hepatocellular carcinomas 51 Glioblastoma Multiforme 51 bladder ovarian 51 metastatic ovarian cancer 51 androgen deficiency 51 Clusterin 51 lobules 51 breast cancer susceptibility genes 51 carotid plaques 51 somatic mutations 51 Endometrial cancer 51 lobular 51 recurrent NSCLC 51 pheochromocytoma 51 GBMs 51 BRCA2 mutation carriers 51 salpingo oophorectomy 51 lymph node 50 colorectal bowel 50 CYP#D# gene 50 pulmonary metastasis 50 cT3 prostate cancer 50 lesions 50 fibrosis 50 indolent NHL 50 schwannomas 50 BRAF protein 50 cytotoxic therapies 50 mammographic density 50 SUVmax 50 H. pylori 50 aerodigestive tract 50 overdiagnosis 50 bronchogenic carcinoma 50 unresectable tumors 50 cervical uterine